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ABSTRACT
Convalescent plasma treatment has become a promising adjunctive option 
to treat COVID-19. Several case reports consistently supported the feasibility 
of this approach by showing the safety and improvements of clinical and 
laboratory aspects from the treated patients. However, more clinical trials 
are still required to establish the definitive statement about its potential 
effectiveness. We review the scientific basis for the application of convalescent 
plasma in COVID-19 to understand its potentials better. We also cover the 
potential risks and benefits for this treatment in order to be more selective 
and careful when preparing and deciding to apply this approach.  Lastly, we 
summarize any important points to monitor after the administration of this 
treatment to prioritize safety and measure the effectiveness of the treatment. 
                        
ABSTRAK
Terapi plasma konvalesen atau plasma sembuh menjadi salah satu pilihan 
terapi pendukung yang menjanjikan pada kasus COVID-19. Beberapa 
laporan kasus yang ada sejauh ini mendukung kelayakan terapi ini dengan 
menunjukan keamanan dan perbaikan-perbaikan baik secara klinis maupun 
laboratoris. Meskipun demikian masih diperlukan uji klinis yang lebih besar 
dan desain studi yang lebih baik untuk sampai pada kesimpulan yang lebih 
meyakinkan mengenai efektivitas terapi ini. Kami merangkum dasar-dasar 
ilmiah penggunaan terapi plasma pada COVID-19 untuk memahami potensinya 
secara lebih baik. Selain itu kami juga meuliskan berbagai keuntungan dan 
juga berbagai risiko yang mungkin terjadi untuk membangun selektifitas dan 
kehati-hatian dalam penggunaannya. Di akhir, kami mencantumkan berbagai 
hal yang penting untuk dimonitor setelah pemberian terapi ini untuk tetap 
mengedepankan prinsip keamanan pada pasien disamping untuk mengukur 
kemanfaatan terapi. 
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INTRODUCTION 
Convalescent plasma (CP) is a 
plasma collected from a patient who 
has survived a previous infection and 
developed humoral immunity against 
the pathogen responsible for the 
disease. The transfusion of CP -a form 
of passive immunization- is expected 
to be able to neutralize the pathogen 
and eventually leads to its eradication 
from the blood circulation.1 Thereof, 
it has been the subject of increasing 
attention, especially during an epidemic. 
The historical perspective of the use of 
convalescent plasma in viral infection 
back to the days of SARS CoV, H5N1 avian 
influenza, Ebola, Middle East Respiratory 
Syndrome (MERS) and H1N1 influenza 
epidemics.2–6 In contrast with active 
vaccination that requires the induction 
of an immune response which takes time 
to develop and varies depending on the 
response of recipient, passive antibody 
administration provides immediate 
immunity to susceptible persons.7 Our 
main objective to write this review was 
to share the scientific grounds of utilizing 
convalescent plasma (CP) in COVID-19.
Since there are two lines of 
immune system against viral infection 
i.e., innate or cellular immunity and 
adaptive or humoral immunity, the 
intriguing question regarding the use of 
convalescent plasma as passive adaptive 
or humoral immunity given to the 
patient would be: which is actually more 
important between innate and adaptive 
immunity in the eradication of SARS-
CoV-2 infection? How necessary is the 
addition of passive adaptive immunity 
for clinical improvement in case of 
COVID-19?
The landscape of the immune 
responses in patients with COVID-19 
is not yet completely clear. However, 
due to similar pathogenesis of SARS-
CoV-2 with previous SARS-CoV infection, 
knowledge learned from SARS-CoV 
has essential points to understand 
the immune responses of this new 
coronavirus. This review will initially 
cover the scientific basis of CP in 
COVID-19 by referring to some articles 
explaining the immunopathogenesis 
of SARS-CoV infection, beside some 
newer review articles that proposed 
the immunopathogenesis of COVID-19. 
This part hopefully would give a defined 
basis to the following sub-topics which 
are more practical issues such as patient 
selection and consideration for timing 
of administration, donor selection and 
monitoring the effect of treatment to 
evaluate safety and effectiveness by 
referring to published works of utilizing 
CP in COVID-19.  
DISCUSSION
Scientific basis of convalescent plasma 
in COVID-19 
Basically, the use of convalescent 
plasma to overcome the infection 
is gained by the administration of 
antibodies contained in the plasma 
against a given agent from a recovered 
patient to an individual for the purpose 
of preventing or treating an infectious 
disease due to the agent. Effective innate 
immune response against viral infection 
relies heavily on the type Iinterferon 
(IFN)  responses by the host upon a viral 
infection and its downstream cascade 
that culminates in controlling viral 
replication and induction of effective 
adaptive immune response.8 Based 
on the accumulated data for previous 
coronavirus infection, innate immune 
response plays crucial role in protective 
or destructive responses. A successful 
mounting of type I IFN response should 
be able to suppress viral replication 
and dissemination at an early stage. 
However, with similar changes in 
increased total neutrophils and decrease 
in lymphocytes counts during COVID19, 
SARS-CoV-2 probably induces delayed 
type I IFN and loss of viral control in 
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an early phase of infection. Active 
viral replication later results in hyper-
production of type I IFN and influx of 
neutrophils and macrophages which are 
the major sources of pro-inflammatory 
cytokines. The stimulation of these innate 
immune cells surrounding the lungs to 
create a cytokine storm by complement 
activation via direct, classical and 
alternative pathways are the main cause 
of acute respiratory distress syndrome 
(ARDS) in later stage of the disease.9,10
Adaptive immunity in the form 
of antibodies play their protective 
functions by several mechanisms : 1) 
antigen neutralization , mainly depends 
on interaction of the antigen-binding 
region (Fab) with antigen, 2)  antibody-
dependent cell-mediated cytotoxicity 
(ADCC) and antibody-dependent cellular 
phagocytosis (ADCP), which require 
interactions between the constant region 
(Fc) of antibody with other proteins or 
immune effector cells. These Fc receptor-
dependent antibody provides a direct 
link between the innate and adaptive 
immune systems, harnessing the potent 
anti-pathogen functions of the innate 
immune system, and overcoming its 
inherent limited pattern recognition 
capacity by utilizing the diversity and 
specificity of the adaptive immune 
response.  Fc receptor-dependent 
antibody provides mechanisms for 
clearance of infected host cells, immune 
complexes, or opsonized pathogens, 
as well as activation of downstream 
adaptive immune responses by 
facilitating antigen presentation 
or by stimulating the secretion of 
inflammatory mediators.11 These two 
mechanisms are generally included in 
the antibody-mediated opsonization. 
The complement-mediated opsonization 
via classical pathway which is another 
protective mechanism of the adaptive 
immune system might work as a double-
edged weapon when it stimulates the 
innate cells,particularly neutrophils 
and macrophages, in the later stage of 
COVID19 to produce enormous amount 
of pro-inflammatory cytokine besides 
those cells infiltration at the site of organ 
dysfunction.10
SARS-CoV infection induces 
seroconversion as early as day 4 after 
onset of disease and was found in 
most patients by 14 days. Long lasting 
specific IgG and neutralizing antibody 
are reported as long as 2 years after 
infection.12 A limited serology details 
of SARS-CoV-2 was reported where a 
patient showed peak specific IgM at day 
9 after disease onset and the switching to 
IgG by week 2.13
Others resumed the two-phase of 
immune response induced by COVID-19 
infection. First or early phase (immune 
defense-based protective phase) consists 
of the incubation and non-severe stage 
where a specific adaptive immune 
response is required to eliminate the 
virus and to preclude disease progression 
to severe stages. They recommend to 
boost the immune system during this 
stage to prevent the disease progression. 
Second or severe phase (inflammation-
driven damaging phase) is where the 
inflammation feature becomes dominant 
causing the organs damage due to 
the impaired early immune response 
followed by the propagation of virus and 
cytokine storm.14
In case of SARS-CoV-2, the anticipated 
mechanism of action by which passive 
antibody therapy would mediate 
protection is by viral neutralization. 
However, the other aforementioned 
mechanisms via ADCC and ADCP may 
also be possible.7
Realizing the intertwine between 
innate and adaptive immune system, 
and how the adaptive immune system 
can back up and even harnessing 
the function of innate immunity, the 
utilization of convalescent plasma in 
COVID-19 patient is a very reasonable 
scientific option. 
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Patient selection and timing of 
administration for the use of 
convalescent plasma in COVID-19: 
balancing risks and benefits
A general principle of passive 
antibody therapy is that it is more 
effective when used for prophylaxis than 
for treatment of disease. When used for 
therapy, passive antibody is most effective 
when administered in earlier stage to 
enable the antibody neutralizing the viral 
antigen more effectively and modifying 
the inflammatory response easily than 
in later or established disease.7However, 
the reason to use it in the later stage 
of the disease is also based on several 
risks. The risks of passive administration 
of convalescent plasma fall into two 
categories, known and theoretical. 
The known risks are those associated 
with transfer of blood substances such 
as infection and any immunological 
reactions. Moreover when transfused 
to individuals with pulmonary disease 
plasma infusion carries some risk for 
transfusion related acute lung injury 
(TRALI).7,15 The theoretical risk involves 
the phenomenon of antibody dependent 
enhancement of infection (ADE) wherein 
normal mechanisms of antigen-antibody 
complex clearance fail, and instead 
provide an alternate route for host cell 
infection.16 For SARS and COVID-19, the 
protein sequences responsible for ADE 
have been identified on the spike (S) 
protein which is the main ligand of the 
SARS-CoV-2 for the entrance to the host 
cell via angiotensin converting enzyme-2 
(ACE-2) receptor.17
Pre-existing anti-CoV IgG antibodies 
to common strains of CoV that infect 
humans, but also react with COVID-19 
and induce ADE could be another risk 
factor for severe disease that partially 
explain its occurrence of in older 
adults.18,19 In other words, the absence 
of high affinity anti-CoV IgG potentially 
explain the milder disease in children 
and younger adults.
Therefore, any efforts should be 
made to increase the potential benefit 
and decrease the risk such as cautious 
preparations from any potential harms 
particularly the preparation of high 
titers of neutralizing antibody that works 
selectively to neutralize SARS-CoV-2 
antigens.20,21
Another theoretical risk is that 
antibody administration to those 
exposed to SARS-CoV-2 may prevent 
disease in a manner that attenuates 
the immune response, causing such 
individuals vulnerable to subsequent 
reinfection. This concern could be 
investigated as part of a clinical trial by 
measuring immune responses in those 
exposed and treated individuals with 
convalescent sera to prevent disease. If 
the risk proved real, these individuals 
could be vaccinated against COVID-19 
when a vaccine becomes available.7
To date only limited clinical trials 
available (6 case reports, by April 20th 
2020,) and all reports applied this 
approach as an adjunctive treatment 
particularly for severe and critically 
ill COVID-19 patient.20–25 From these 
publications including 27 patients (1 
mild aymptomatic, 1 moderately ill, 16 
severe and 9 critical ill) there was only 
one mild immunological reaction in form 
of facial red spot, not a life-threatening 
condition.21 The approval from FDA are 
also still limited convalescent plasma for 
severe and critically ill COVID-19.26
Beside any scientific considerations, 
this selection may be based on the 
facts that there is not yet any specific 
treatment for this disease. Allowing the 
immune defense-based protective phase 
to work optimally during the initial stage 
could be one of the safest way, although 
it does not prevent any further trial to 
apply this treatment for earlier stage or 
even possibly be a prophylaxis.7,27
Donor selection
Convalescent plasma is drawn from 
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individuals who have recovered from 
COVID-19 who can donate blood, have 
had no symptoms for 14 days, and have 
had negative results on covid-19 tests.26 
General eligibility criteria for blood 
donation and vigilant procedures for 
screening any potential infections and 
transfusion reactions should be done. 
More important, the sufficiently high 
amount of antibody IgG titer by ELISA 
as well as appropriate anti-SARS-CoV-2 
neutralizing antibody titer should be 
verified before the donation.20,21,27 Some 
studies showed that ELISA IgG correlates 
well with neutralization titers in MERS 
cases so that it might be a sufficient 
screening test for plasma donation.17,28 
Four among six case reports that applied 
CP in COVID-19 did not mention any 
measurement of neutralizing antibody 
titers, including one case report from 
Korea that presumed its high titer due to 
history of severe clinical condition of the 
donors.22–25 After the qualification of the 
donor, plasma collection can be done.
Plasmapharesis is a preferred collection 
method. The most important reason 
for this method is the possible larger 
collected volume and less impact on the 
donor’s haemoglobin level. A repetition 
of donation with 2 weeks intervals is 
also possible with plasmapharesis.27 
A blood donation followed by plasma 
fractionation is another method to 
obtain convalescent plasma that may 
become an option when plasmapharesis 
equipment is not available.
Monitoring the effect of treatment: 
safety and effectiveness
Safety and effectiveness are two 
important points to assess in the patient 
after the administration of convalescent 
plasma product. Close monitoring 
should be maintained during and after 
transfusion to detect any transfusion-
related immediate adverse effects such 
as transfusion-associated circulation 
overload (TACO) and to detect any further 
unintended side effects which usually be 
related to any immunological reactions, 
particulary transfusion related acute 
lung injury (TRALI) or any systemic 
complications.27
The effectiveness of convalescent 
plasma treatment can be assessed from 
four aspects, as follow :
1) Clinical recovery response. From a 
variety of case series or clinical trials with 
limited subjects investigating the effect 
of convalescent plasma to COVID-19 
patients, clinical parameters occupy 
top priority in assessing effectiveness, 
including resolution of symptoms such 
as dyspnea due to renormalization of 
blood oxygen saturation (SaO2), changes 
in vital signs such as body temperature 
which turns into normal, or other 
important clinical outcomes such as 
extubation in previous ARDS patients, 
discharge from hospital, or patients 
with fatal conditions that die later.20–22,25 
Convalescent plasma obtained from 
recovered COVID-19 patients are 
considered to have humoral immunity, 
which is later perceived to have high 
levels of neutralizing antibodies that are 
sufficiently capable and could contribute 
to the viral clearance and symptom 
improvement.20,21 In addition, evidenced 
from in vivo study of HIV-1 virus, it was 
reported that neutralizing antibodies 
could also increase the clearance of 
infected cells which also provide to 
alleviation of symptoms.29
2) Measurement of the antibody 
titers. In line with the previous point, it 
is known that virus-specific IgM and IgG 
antibody titers, including neutralizing 
antibody levels, are considered as the 
eligibility criteria of plasma donor 
candidate with variable cut-off titer 
between studies.20,21,25,27 This shows 
that antibody parameters, including 
neutralization antibodies, are one of the 
most important therapeutic mechanisms 
of convalescent plasma. It is known 
from previous reports, that patients 
who recovered from SARS-CoV infection 
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will experience a slow but persistent 
increase in neutralizing antibody titers 
which is not observed in dead cases.30 
In conjunction with standard therapy, 
neutralizing antibodies in convalescent 
plasma will accelerate virus clearance 
and prevent the viral entry into the target 
cells.31 Convalescent plasma transfusion 
is expected to contribute in increasing 
polyclonal antibody and neutralizing 
antibodies titers in COVID-19 patients 
which result on virus neutralization 
and lead to symptom improvement. 
Consequently, serial measurement of 
antibody titers in terms of IgM, IgG, and 
neutralizing antibodies titersarehighly 
recommended to monitor the therapeutic 
effectiveness.20
3) Resolution of acute inflammatory 
parameters. As with other infectious 
diseases, SARS-CoV-2 infection will cause 
an influx of neutrophils and monocytes/
macrophages which results in hyper-
production of pro-inflammatory 
cytokine.9  Most COVID-19 cases will be 
followed by an increase in neutrophils, 
decreased of lymphocytes, increased of 
IL-6 and CRP level, with in severe patients 
followed by elevation of Procalcitonin.32,33 
These parameters generally reflect acute 
yet severe inflammation occurred within 
SARS-CoV-2 infection. Based on previous 
studies, administration of standard 
therapy in conjunction with convalescent 
plasma was followed by decrease in pro-
inflammatory parameters such as IL-6, 
CRP, and pro-calcitonin level, in addition 
to re-normalization of lymphocytes 
counts.20–22 Contribution of neutralizing 
antibodies within convalescent plasma 
along with gaining function of patient’s 
adaptive humoral immunity to undergo 
self-production of antibodies further 
helps accelerate viral clearance and 
ultimately reduce acute inflammatory 
effects of SARS-CoV-2 infection. 
Therefore, measurement of acute 
inflammatory parameters reflected by 
differential counts, CRP, pro-calcitonin 
and IL-6 is recommended to be a part 
of evaluation of convalescent plasma 
transfusion.
4) Resolution of the imaging 
result. Along with the improvement 
of pneumonia in COVID-19 patients 
clinically, it will also be followed by 
resolution of lung imaging. It was 
previously known that ground-glass 
opacities (GGO) and lung consolidation 
are the predominant findings in majority 
of COVID-19 cases with pneumonia.34 
Despite lower sensitivity compared 
with CT scans to detect abnormalities 
in COVID-19, chest X-ray is still being 
considered as first choice of imaging 
modality to triage the suspected cases in 
some countries, including Indonesia, due 
to limitation of CT facilities but relatively 
more affordable portable X-Ray with less 
risk of contamination.35 Some studies 
reported improvement in terms of lung 
imaging within a week after transfusion 
of convalescent plasma, although they 
used serial CT scan.21,23 Considering the 
similarity of findings between CT scans 
and chest X-rays in majority of COVID-19 
cases with pneumonia,  it is still possible to 
see these improvements with serial chest 
X-Ray which has also been reported by a 
case series in South Korea.22 Therefore, 
radiological improvement could bring 
additional evidence of convalescent 
plasma effectiveness accompanied 
by monitoring of clinical status and 
laboratory parameters.
CONCLUSION 
Convalescent plasma as adjunctive 
treatment for COVID-19 has a strong 
scientific basis to be utilized. Awareness 
of its potential risks and benefit help to 
determine the strategies to improve the 
treatment outcome and minimize the 
adverse events. Safety and effectiveness 
are two important points to assess in 
the patient following the treatment to 
study the benefit and risk better and to 
define the effectiveness of treatment. 
Last but not least, despite still limited 
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in the number of reports, the data 
consistently showed encouraging 
comprehensive result from the patients. 
More expanded clinical trials with more 
patients in number and better study 
designs are required to draw a more 
definitive statement about its potential 
effectiveness. 
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